# Stevanato Group S.p.A. share price today (Stevanato Group S.p.A., STVN)

> Stevanato Group S.p.A.'s earnings have grown faster than its share price. Earnings per share grew +18.6% in a year while the price moved −44.1%. STVN · Healthcare · Medical Instruments & Supplies · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/stvn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $14.10 (−44.1% in a year)
- P/E: 24.4×, over 4.6 years
- Revenue (Jun 2026): $302 M (+7.8% on a year ago)
- Profit (Jun 2026): $23.0 M (−22.7% on a year ago)
- Operating margin: 17.2% (+2.2 points on a year ago)
- ROE: 9%, FY25
- ROIC: 8.1%, against a 7.8% cost of capital: +0.3 points

The main question: yearly earnings per share moved +18.6% while the share price moved −44.1%. ## What is the Stevanato Group S.p.A. share price today? Stevanato Group S.p.A.'s share price was $14.10 at the close on 3 November 2026. It has been falling for 1 week. That is 22.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $13 and $24, and at that close it sat 6% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 5 weeks running. Over the last 5.3 years the share price moved −31% while the S&P 500 moved +71%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 2 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Stevanato Group S.p.A. pay? Stevanato Group S.p.A. has 2 quarters of declared dividends on file, too few for a 12-month total. The most recent declaration was $0.05 for Dec 2024. Stevanato Group S.p.A. declared a dividend in 2 of the last 12 reported quarters, most recently $0.05 for Dec 2024. That is fewer than four quarters, so no 12-month total is shown. ## Which stock lists is Stevanato Group S.p.A. on? Stevanato Group S.p.A. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Stevanato Group S.p.A. profitable? Stevanato Group S.p.A. earned $23.0 M of net profit in the Jun 2026 quarter, −22.7% on the same quarter a year earlier. Full-year FY25 profit was $140 M. Over 4 years profit has grown 1.0% a year on average. That is 7.6% of the quarter's revenue. The same quarter a year earlier earned $29.7 M. For the full year, FY25 profit was $140 M (+18.7% on the year before). Why profit moved: revenue changed +7.8% on a year earlier and the margin moved +2.2 percentage points. Most of the change came from keeping more of each sale. On average over the last four quarters, profit changed +0.4% and revenue +7.1%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Stevanato Group S.p.A. make, and is it growing? Stevanato Group S.p.A. reported $302 M of revenue in the Jun 2026 quarter, +7.8% on the same quarter a year earlier. That is the 9th quarter in a row with growth on the year before. Over 4 years it has grown 8.9% a year on average. The last full year, FY25, came in at $1.2 B. The last four reported quarters add to $1.2 B. FY25 revenue was $1.2 B, +7.4% on the year before. Recent pace: the last four quarters grew +7.1% on average, against 8.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +7.0%, against +6.1% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +0.0%, against +4.8% a year (rolling over). ## How much of every $100 of sales does Stevanato Group S.p.A. keep? Stevanato Group S.p.A.'s operating margin was 17.2% in the Jun 2026 quarter, 2.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between 15.2% and 19.6%. The latest quarter is within that range. Why the margin moved: operating margin changed +2.2 percentage points on the year while gross margin changed +0.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Stevanato Group S.p.A.'s profit turning into cash? Over the last 3 years, 136% of Stevanato Group S.p.A.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $286 M of operating cash against $140 M of profit. After $264 M of spending on assets, $22.3 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Stevanato Group S.p.A.'s cash go? Stevanato Group S.p.A. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1,000 M on assets over the last 3 years. Averaged over those years that is 28.1% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1,000 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Stevanato Group S.p.A.'s P/E ratio, and how does it compare with its own history? Stevanato Group S.p.A.'s P/E is 24.4×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +18.6% while the price moved −44.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 3 years the price moved −19.1% a year; about −4.8% a year came from earnings growth and about −14.3 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Stevanato Group S.p.A. business getting better or worse? Stevanato Group S.p.A.'s business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 11.1%; each line tells part of the story. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Stevanato Group S.p.A. earn on its capital? Stevanato Group S.p.A. earned a ROE of 9% in FY25. That is up from a low of 8% in FY24. Its return on capital used (ROIC) is 0.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 11.8% net margin and 0.47× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 11.8% net margin × 0.47× asset turnover × 1.71× leverage (assets divided by equity) ≈ 9.5% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 8.1% − 7.8% = +0.3 percentage points. The 7.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Stevanato Group S.p.A. have too much debt? Stevanato Group S.p.A. has total debt of $445 M against shareholder equity of $1.5 B as of Jun 2026, so its debt is 0.29× its equity, which is very little. Year by year, that ratio went from 0.30 in FY21 to 0.32 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Stevanato Group S.p.A. shareholding pattern? 2.0% of Stevanato Group S.p.A.'s tradable shares are in short positions, which are bets that the price will fall, so very few traders are betting against this stock. At normal trading volumes, closing those positions would take about 3.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Stevanato Group S.p.A. from balance-sheet trouble? For Stevanato Group S.p.A., the Z-score is 4.14. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.14 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Stevanato Group S.p.A. rank in its industry? 43.7 out of 100, rank 20 of 30 in Medical Instruments & Supplies, with 81% of the evidence available. Stevanato Group S.p.A. scores 43.7 out of 100 against the 30 companies it is compared with in Medical Instruments & Supplies, ranking 20. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 17.1 + 16.1 + 10.5 + 0 = 43.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Stevanato Group S.p.A. compared with? Stevanato Group S.p.A. ranks 20 of 30 Medical Instruments & Supplies companies on the 4-Factor Sector Score, with 43.7 out of 100. 1. [West Pharmaceutical Services, Inc.](https://www.sectoralpha.in/us/stocks/wst) WST · breaking out · Most evidence points up · 81% evidence 68.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.5/35 · Revenue 12.4% · Profit 15.8% · Operating margin change 1.6 points · 83% evidence Capital efficiency 20.6/25 · ROCE 21.2% · Operating margin 22.5% · 76% evidence Valuation 7.0/20 · P/E 44.9× · PEG 2.65 · 65% evidence Relative strength 17.7/20 · Lead over its industry 15.3% · Lead over S&P 500 26.8% · 1 year 50.2% · 100% evidence · 5 of 12 weeks ahead Exact sum: 23.5 + 20.6 + 7 + 17.7 = 68.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [LeMaitre Vascular, Inc.](https://www.sectoralpha.in/us/stocks/lmat) LMAT · turning · Evidence leans up · 81% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.7/35 · Revenue 11.5% · Profit 40.4% · Operating margin change 3.9 points · 83% evidence Capital efficiency 17.3/25 · ROCE 11.9% · Operating margin 29% · 76% evidence Valuation 14.0/20 · P/E 33.4× · PEG 0.86 · 65% evidence Relative strength 4.1/20 · Lead over its industry -25.2% · Lead over S&P 500 -17.1% · 1 year -7.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.7 + 17.3 + 14 + 4.1 = 62.1 · What this means: Earnings are strong; relative strength in its sector is -25.2% and the one-year return is -7.2%. 3. [Intuitive Surgical, Inc.](https://www.sectoralpha.in/us/stocks/isrg) ISRG · breaking out · Evidence leans up · 85% evidence 60.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.8/35 · Revenue 20.4% · Profit 7.7% · Operating margin change 3 points · 95% evidence Capital efficiency 21.4/25 · ROCE 22% · Operating margin 33.3% · 76% evidence Valuation 4.5/20 · P/E 48.6× · PEG 5.33 · 65% evidence Relative strength 8.0/20 · Lead over its industry -17.1% · Lead over S&P 500 -8.6% · 1 year -21.3% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.8 + 21.4 + 4.5 + 8 = 60.7 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 4. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) ATRC · leader · Evidence leans up · 64% evidence 58.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue 14% · Profit n/a · Operating margin change 10.8 points · 62% evidence Capital efficiency 6.1/25 · ROCE 2.2% · Operating margin 6.3% · 76% evidence Valuation 8.9/20 · P/E 134.3× · PEG n/a · 15% evidence Relative strength 19.6/20 · Lead over its industry 37.3% · Lead over S&P 500 49.6% · 1 year 88.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.2 + 6.1 + 8.9 + 19.6 = 58.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [ResMed Inc.](https://www.sectoralpha.in/us/stocks/rmd) RMD · breaking out · Evidence leans up · 81% evidence 57.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 9.8% · Profit 8.8% · Operating margin change -3 points · 83% evidence Capital efficiency 21.5/25 · ROCE 25.4% · Operating margin 30.9% · 76% evidence Valuation 10.2/20 · P/E 18.5× · PEG 1.91 · 65% evidence Relative strength 8.0/20 · Lead over its industry -14.3% · Lead over S&P 500 -5.8% · 1 year -9.7% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.8 + 21.5 + 10.2 + 8 = 57.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch + Lomb Corporation](https://www.sectoralpha.in/us/stocks/blco) BLCO · turning · Evidence leans up · 64% evidence 56.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 8.8% · Profit n/a · Operating margin change 6.8 points · 62% evidence Capital efficiency 7.2/25 · ROCE 3.4% · Operating margin 7.7% · 76% evidence Valuation 11.5/20 · P/E -18.5× · PEG n/a · 15% evidence Relative strength 16.3/20 · Lead over its industry 3.6% · Lead over S&P 500 14% · 1 year 28.8% · 100% evidence · 8 of 12 weeks ahead Exact sum: 21.4 + 7.2 + 11.5 + 16.3 = 56.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) MMSI · quiet · Evidence leans up · 81% evidence 55.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.0/35 · Revenue 10.3% · Profit 22.7% · Operating margin change 2.2 points · 83% evidence Capital efficiency 14.3/25 · ROCE 8.1% · Operating margin 14.5% · 76% evidence Valuation 12.7/20 · P/E 28.4× · PEG 1.22 · 65% evidence Relative strength 6.6/20 · Lead over its industry -7% · Lead over S&P 500 1.8% · 1 year -3.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22 + 14.3 + 12.7 + 6.6 = 55.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Kestra Medical Technologies, Ltd.](https://www.sectoralpha.in/us/stocks/kmts) KMTS · breaking out · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.1/35 · Revenue 63.6% · Profit n/a · Operating margin change 27.5 points · 71% evidence Capital efficiency 3.4/25 · ROCE -48% · Operating margin -121.6% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 15.6/20 · Lead over its industry 4.2% · Lead over S&P 500 14.3% · 1 year 10.6% · 100% evidence · 9 of 12 weeks ahead Exact sum: 25.1 + 3.4 + 10 + 15.6 = 54.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Becton, Dickinson and Company](https://www.sectoralpha.in/us/stocks/bdx) BDX · breaking out · Evidence leans up · 71% evidence 51.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 5.8% · Profit -40.6% · Operating margin change -1.4 points · 83% evidence Capital efficiency 13.6/25 · ROCE 7.6% · Operating margin 15.7% · 76% evidence Valuation 9.6/20 · P/E 44.3× · PEG n/a · 15% evidence Relative strength 13.6/20 · Lead over its industry -2% · Lead over S&P 500 7.5% · 1 year 11.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 14.2 + 13.6 + 9.6 + 13.6 = 51 · What this means: Relative strength against the index is 7.5%, and revenue and profit growth are weak. 10. [Repligen Corporation](https://www.sectoralpha.in/us/stocks/rgen) RGEN · leader · Evidence leans up · 74% evidence 50.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 16.5% · Profit n/a · Operating margin change 4.8 points · 62% evidence Capital efficiency 8.9/25 · ROCE 2.3% · Operating margin 9.3% · 76% evidence Valuation 3.7/20 · P/E 185.3× · PEG 8.54 · 65% evidence Relative strength 15.3/20 · Lead over its industry 5% · Lead over S&P 500 15% · 1 year 24.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.6 + 8.9 + 3.7 + 15.3 = 50.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Baxter International Inc.](https://www.sectoralpha.in/us/stocks/bax) BAX · quiet · Evidence leans up · 64% evidence 50.1 out of 100 Growth Capital Valuation Relative
12. [The Cooper Companies, Inc.](https://www.sectoralpha.in/us/stocks/coo) COO · basing · Evidence leans down · 85% evidence 49.5 out of 100 Growth Capital Valuation Relative
13. [STAAR Surgical Company](https://www.sectoralpha.in/us/stocks/staa) STAA · turning · Too little evidence to rank firmly · 58% evidence 49.2 out of 100 Growth Capital Valuation Relative
14. [Avantor, Inc.](https://www.sectoralpha.in/us/stocks/avtr) AVTR · leader · Evidence leans down · 71% evidence 48.7 out of 100 Growth Capital Valuation Relative
15. [Solventum Corporation](https://www.sectoralpha.in/us/stocks/solv) SOLV · losing its lead · Evidence leans down · 71% evidence 48.3 out of 100 Growth Capital Valuation Relative
16. [Alcon Inc.](https://www.sectoralpha.in/us/stocks/alc) ALC · turning · Evidence leans down · 61% evidence 47.0 out of 100 Growth Capital Valuation Relative
17. [Azenta, Inc.](https://www.sectoralpha.in/us/stocks/azta) AZTA · leader · Evidence leans down · 64% evidence 46.6 out of 100 Growth Capital Valuation Relative
18. [AptarGroup, Inc.](https://www.sectoralpha.in/us/stocks/atr) ATR · turning · Evidence leans down · 81% evidence 45.6 out of 100 Growth Capital Valuation Relative
19. [Align Technology, Inc.](https://www.sectoralpha.in/us/stocks/algn) ALGN · quiet · Evidence leans down · 81% evidence 44.1 out of 100 Growth Capital Valuation Relative
20. Stevanato Group S.p.A. this page STVN · quiet · Evidence leans down · 81% evidence 43.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.1/35 · Revenue 6.9% · Profit 0% · Operating margin change 2.2 points · 83% evidence Capital efficiency 16.1/25 · ROCE 10.6% · Operating margin 17.2% · 76% evidence Valuation 10.5/20 · P/E 32.1× · PEG 1.73 · 65% evidence Relative strength 0.0/20 · Lead over its industry -34.1% · Lead over S&P 500 -27.6% · 1 year -41.5% · 100% evidence · 6 of 12 weeks ahead Exact sum: 17.1 + 16.1 + 10.5 + 0 = 43.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 21. [Envista Holdings Corporation](https://www.sectoralpha.in/us/stocks/nvst) NVST · quiet · Too little evidence to rank firmly · 58% evidence 43.2 out of 100 Growth Capital Valuation Relative
22. [Teleflex Incorporated](https://www.sectoralpha.in/us/stocks/tfx) TFX · turning · Evidence leans down · 71% evidence 42.0 out of 100 Growth Capital Valuation Relative
23. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) ICUI · quiet · Evidence leans down · 64% evidence 37.6 out of 100 Growth Capital Valuation Relative
24. [Medline Inc.](https://www.sectoralpha.in/us/stocks/mdln) MDLN · quiet · Too little evidence to rank firmly · 51% evidence 37.3 out of 100 Growth Capital Valuation Relative
25. [DENTSPLY SIRONA Inc.](https://www.sectoralpha.in/us/stocks/xray) XRAY · basing · Most evidence points down · 64% evidence 31.0 out of 100 Growth Capital Valuation Relative
26. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) WRBY · quiet · Most evidence points down · 64% evidence 30.1 out of 100 Growth Capital Valuation Relative
27. [BioLife Solutions, Inc.](https://www.sectoralpha.in/us/stocks/blfs) BLFS · Too little evidence to rank firmly · 44% evidence 48.0 out of 100 Growth Capital Valuation Relative
28. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) PLSE · leader · Too little evidence to rank firmly · 41% evidence 44.0 out of 100 Growth Capital Valuation Relative
29. [MiniMed Group, Inc.](https://www.sectoralpha.in/us/stocks/mmed) MMED · quiet · Too little evidence to rank firmly · 41% evidence 39.1 out of 100 Growth Capital Valuation Relative
30. [Alamar Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/almr) ALMR · turning · Too little evidence to rank firmly · 28% evidence 38.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Instruments & Supplies](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies), all 30 compared on one page. ## Which companies are close to Stevanato Group S.p.A. in size? Stevanato Group S.p.A. is the 20th largest of 38 Medical Instruments & Supplies companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Merit Medical Systems, Inc., ICU Medical, Inc. and Envista Holdings Corporation. Just below it: Pulse Biosciences, Inc., AtriCure, Inc. and Warby Parker Inc. ### Medical Instruments & Supplies companies close in size

1. [Merit Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/mmsi) $5 billion
2. [ICU Medical, Inc.](https://www.sectoralpha.in/us/stocks/icui) $4 billion
3. [Envista Holdings Corporation](https://www.sectoralpha.in/us/stocks/nvst) $4 billion
4. Stevanato Group S.p.A. $3.9 billion
5. [Pulse Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/plse) $3.7 billion
6. [AtriCure, Inc.](https://www.sectoralpha.in/us/stocks/atrc) $3.1 billion
7. [Warby Parker Inc.](https://www.sectoralpha.in/us/stocks/wrby) $2.7 billion

[All 38 Medical Instruments & Supplies companies, largest first](https://www.sectoralpha.in/us/sectors/medical-instruments-supplies#all-companies)

### Companies close in size in other industries

1. [Portland General Electric Company](https://www.sectoralpha.in/us/stocks/por) $5.4 billion · Utilities - Regulated Electric
2. [Waystar Holding Corp.](https://www.sectoralpha.in/us/stocks/way) $5.4 billion · Health Information Services
3. Stevanato Group S.p.A. $5.4 billion
4. [CNO Financial Group, Inc.](https://www.sectoralpha.in/us/stocks/cno) $5.4 billion · Insurance - Life
5. [Remitly Global, Inc.](https://www.sectoralpha.in/us/stocks/rely) $5.4 billion · Software - Infrastructure

## What else do people ask about Stevanato Group S.p.A.? ### What were Stevanato Group S.p.A.'s latest quarterly results? Stevanato Group S.p.A. reported revenue of $302 M and net profit of $23.0 M for the Jun 2026 quarter. Revenue rose 7.8% and profit fell 22.7% compared with a year earlier. Earnings per share were $0.08. The operating margin was 17.2%, 2.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Stevanato Group S.p.A.'s market cap? Stevanato Group S.p.A.'s market capitalisation is $3.9 B at a stock price of $14.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Stevanato Group S.p.A. performing? Stevanato Group S.p.A.'s share price has been falling for 1 weeks. In its latest quarter, revenue rose 7.8% and profit fell 22.7% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 5 weeks running (as of 3 November 2026). ### Will Stevanato Group S.p.A.'s stock price go up? This page does not forecast Stevanato Group S.p.A.'s stock price. What it shows instead: the stock price is $14.10, and it has been falling for 1 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Does Stevanato Group S.p.A. have too much debt? No, Stevanato Group S.p.A. has little debt: its debt is 0.22× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. So the returns on this page come from the business, not borrowed money (as of 3 November 2026). ### Where is Stevanato Group S.p.A. in its business cycle? Stevanato Group S.p.A.'s FY25 operating margin was 17.2%, against a 5-year range of 15.2% to 19.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 17.2%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Stevanato Group S.p.A. story? The main question: yearly earnings per share moved +18.6% while the share price moved −44.1%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Stevanato Group S.p.A. a stock worth studying right now? What the numbers show: Stevanato Group S.p.A.'s earnings have grown faster than its share price. Earnings per share grew +18.6% in a year while the price moved −44.1%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.